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Background: Many patients are diagnosed with cancer through the emergency path-
way; a route which is associated with inferior outcomes and increased costs to the
patient and healthcare system. Lung cancer constitutes the largest proportion of emer-
gency presentations (EP). Small cell lung cancer (SCLC), which represents only 10-15%
of all lung cancers, constitutes a disproportionate amount of presentations via the
emergency route.
Methods: Data was collected retrospectively from four non-teaching hospitals in the
United Kingdom over the period of January to December 2016. Only patients with his-
tological confirmation of SCLC were included. We compared the EP population with
the population who presented electively in the following categories: - demographics -
performance status - stage at presentation of disease - proportion who proceeded to
have chemotherapy - the survival data for this group of patients.
Results: 80 patients were identified across four hospitals. 33% (n¼ 27) presented via






70.4 years Age at presentation 69.4 years
49% Proportion of Males 37%
69.8% Proportion of Extensive
Disease at Presentation
88%
1.68 Mean Performance Status 1.81
66% Proportion who Received
Systemic Treatment
55%
86.7% Proportion alive at 30 days 44%
64.1% Proportion alive at 90 days 40.70%
60.7% Proportion alive at 180 days 14.8%
The demographics of the two sub-groups are comparable, although there is a higher
proportion of patients with extensive disease in the EP group (88% vs 69.8%). While
the proportion who received systemic treatment was only marginally higher in the elec-
tive referral route (66% vs 55%), there was a substantial difference in overall survival.
The divergence in the Kaplan-Meier curves occur most markedly within the first 30-
days.
Conclusions: 1. A disproportionately high number of SCLC present via the Emergency
Pathway, which is predictable due to its rapidly progressing nature. 2. Apart from the
extent of disease, the demographics between both sub-groups are comparable, includ-
ing performance status and even proportion who received systemic treatment. 3. There
is a substantial difference in overall survival between the two subgroups, with diver-
gence especially within the first month after diagnosis in their Kaplan-Meier curves. 4.
This suggests that earlier diagnosis of SCLC is crucial to improving outcomes, inde-
pendent of all other factors. Due to the strong association between smoking and SCLC,
this study lands support towards a risk-based screening programme utilising low-dose
computerised tomography
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Background: Amrubicin is one of the most active chemotherapeutic agents for small-
cell lung cancer (SCLC). Previous studies reported its effectiveness and severe hemato-
logical toxicity. However, the efficacy of amrubicin monotherapy in elderly patients
with SCLC has not been described. The objective of this study was to investigate the fea-
sibility of amrubicin monotherapy in elderly patients, and its efficacy for relapsed
SCLC.
Methods: A retrospective cohort study design was used. We retrospectively evaluated
the clinical effects and adverse events of amrubicin treatment in elderly (70 years)
SCLC patients with relapsed SCLC.
Results: Between November 2003 and September 2015, 86 patients (aged70 years)
received amrubicin monotherapy for relapsed SCLC at four institutions. There were 42
cases of sensitive relapse (S) and 44 of refractory relapse (R). S cases with median age of
75 years (range, 70–85 years) and R cases with median age of 74 years (range, 70–84
years) were included in our analysis. The median number of treatment cycles was 3
(range 1–9), and the response rate was 33.7% (40.5% in the S and 27.2% in the R cases).
Median progression-free survival time was 4.0 months in the S and 2.7 months in the R
patients (p¼ 0.013). Median survival time from the start of amrubicin therapy was 7.6
months in the S and 5.5 months in the R cases (p¼ 0.26). The frequencies of grade3
hematological toxicities were as follows: leukopenia, 60.4%; neutropenia, 74.4%; ane-
mia, 11.6%; thrombocytopenia, 16.2%; and febrile neutropenia, 17.4%. Treatment-
related death was observed in 1 patient.
Conclusions: Although hematological toxicities, particularly neutropenia, were severe,
amrubicin showed excellent anti-tumor activity, not only in the S, but also in the R
cases, as shown in previous studies. Amrubicin could be a preferable standard treat-
ment in elderly patients with relapsed SCLC. These results warrant further evaluation
of amrubicin in elderly patients with relapsed SCLC by a prospective trial.
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Background: Patients with epidermal growth factor receptor (EGFR) mutant advanced
non-small cell lung cancer (NSCLC) developed resistance to first- or second-generation
EGFR-tyrosine kinase inhibitor (TKI) after 9-13 months and third-generation EGFR-
TKI after 10 months, respectively. Small cell lung cancer (SCLC) transformation is a
rare resistance mechanism in these patients.
Methods: Tissue re-biopsy in 35 patients with EGFR mutant advanced NSCLC who
failed first-line EGFR-TKI; and 4 patients with acquired T790M mutant advanced
NSCLC who failed third-generation EGFR-TKI, to look for SCLC transformation.
Results: SCLC transformation was identified in 2 out of 35 (5.7%) patients who failed
first-line EGFR-TKI and 1 out of 4 (25.0%) patients who failed third-generation EGFR-
TKI. All 3 patients were never smoker. The first patient was a 70-year-old male with
exon 19 deletion stage IV lung adenocarcinoma. He had partial response (PR) to gefiti-
nib 250 mg daily but developed symptomatic progressive disease (PD) after 26 months.
Re-biopsy of his enlarging primary lung lesion showed SCLC transformation. The sec-
ond patient was a 43-year-old male with exon 19 deletion stage IV lung adenocarci-
noma. He had PR to gefitinib 250 mg daily but developed symptomatic PD after 15
months. Re-biopsy of his enlarging primary lung lesion showed SCLC transformation
and plasma was positive for T790M mutation. The third patient was a 62-year-old
female with exon 21 L858R stage IV lung adenocarcinoma. She had PR to gefitinib
250 mg daily but experienced symptomatic PD after 8 months’ of gefitinib therapy. Re-
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biopsy of her primary lung tumor revealed T790M mutation and treatment was
switched to osimertinib 80 mg daily. After an initial PR, she developed PR in the 12th
month. Biopsy from metastatic inguinal lymph node showed SCLC. The first and sec-
ond patients were given standard chemotherapy but did not respond. The third patient
sought treatment in another hospital.
Conclusions: Re-biopsy is recommended in patients with symptomatic PD while on
EGFR-TKI treatment. SCLC transformation is an emerging challenge to the manage-
ment of advanced NSCLC. New treatment strategies should be explored to improve
outcome of patients who develop SCLC transformation.
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Background: The importance of nutritional status and chronic inflammation has been
emphasized in cancer. We investigated the impact of the Onodera’s prognostic nutri-
tional index (PNI) on clinical outcomes in patients with small cell lung cancer (SCLC).
Methods: Data of 220 SCLC patients treated with first-line platinum-based chemother-
apy from 2006 to 2017 were retrospectively reviewed. The PNI was calculated as 10
serum albumin (g/dL)þ 0.005 absolute lymphocyte count (/mm3). Those with the
PNI> 45, 40 – 45, and< 40 were categorized as high, intermediate, and low PNI
groups, respectively.
Results: The proportion of non-responders to first-line therapy was significantly
increased as the PNI was decreased (high, intermediate, and low PNI group, 6.7%,
18.0%, and 30.8%, p< 0.001). Early discontinuation of first-line therapy due to treat-
ment related toxicity occurred more frequently in lower PNI group (high, intermediate,
and low PNI group, 5.8%, 21.3%, and 25.6%, p< 0.001). The 1-year progression-free
survival (PFS) and overall survival (OS) rates were 29% and 61%, 19% and 46%, and
3% and 23% in high, intermediate, and low PNI group, respectively. On multivariate
analyses, the low PNI group was independently associated with poor PFS (HR¼ 1.592,
95% CI¼ 1.009 – 2.511, p¼ 0.046) and OS (HR¼ 1.911, 95% CI¼ 1.208 – 3.024, p¼
0.006) compared with the high PNI group.
Conclusions: SCLC patients with the PNI< 40 showed low treatment response rate,
intolerance to chemotherapy, and poor prognosis. Further evaluation is needed to vali-
date this findings.
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Background: The number of available regimens which can be used in relapsed small-
cell lung cancer (SCLC) is small and the data of the regimens is lack than those of non-
small cell lung cancer. The goal of the present study is to evaluate the clinical outcome
of ifosfamide and carboplatin (IC) regimen for third- or further-line chemotherapy in
SCLC patients.
Methods: A retrospective analysis was conducted of all patients who received combina-
tion chemotherapy with IC regimenbetween 2011 and 2015 for SCLC. The data
included baseline demographics, chemotherapy-related toxicities, therapeutic regi-
mens that used and survival period.
Results: A total of 12 patients were administered IC regimen. All of the IC regimens
were used in third- or further-line chemotherapy and 9 (75%) of cases were fourth-line
therapy. Of the 37 chemotherapy-related toxicity events, 27 (73%) were hematologic
toxicities and thrombocytopenia (n¼ 10 (27%)) was reported most frequently. The
median overall survival (OS) after IC administration was 3.5 months. Patients with
positive change of body mass index (BMI) before IC administration (p¼ 0.071), with-
out multiple metastases at start of IC regimen (p¼ 0.001), refractory relapse after first
line treatment (p¼ 0.082), partial response or stable disease to the IC treatment
(p¼ 0.007) showed longer duration of OS.
Table: 500P Patient characteristics (n¼12) at diagnosis and
point of IC administration
Parameter Value
Male 10 (83.3%)







SMK: median (range) 40 (0-80) packyears
BMI: median (range)
at diagnosis 23.31 (16.93-31.75) kg/m2
pre-IC 23.07 (18.58-29.79) kg/m2
Pre-IC albumiin: median (range) 3.75 (3.3-4.1) mg/dL
Pre-IC LDH: median (range) 510.50 (367-1245) U/L
Pre-IC Sodium: median (range) 135.70 (125.60-
138.50) mEq/L
Pre-IC Hb: median (range) 11.30 (9.3-13.4) g/dL
TNM staging at diagnosis
IIIB 2 (16.7%)
IV 10 (83.3%)
VALG staging at diagnosis
LD 2 (16.7%)
ED 10 (83.3%)
Multiple metastases at start of IC regimen
No 5 (41.7%)
Yes 7 (58.3%)
Type of relapase after 1st line treatment
Sensitive 6 (50%)
Refractory 6 (50%)












Conclusions: The IC regimen is a reasonable therapeutic arm for relapsed SCLC.
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